A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis

Trial Profile

A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 03 May 2013

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STAY
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 May 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 26 Mar 2013 Planned initiation date changed from 1 Oct 2012 to NULL.
    • 25 Feb 2013 Status changed from not yet recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top